Skip to main content
SpringerLink
Log in

Outcome Measures and Prognostic Markers for COPD

  • Chapter
  • First Online:
COPD

Part of the book series: Respiratory Medicine ((RM))

  • 5204 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Celli BR, MacNee W (2004) Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS paper. Eur Respir J 23:932–946

    CAS  PubMed  Google Scholar 

  2. Tashkin DP (2006) Introduction. Am J Med 119(10 Suppl 1):1–3

    PubMed  Google Scholar 

  3. Wise RA (2006) The value of forced expiratory volume in 1 second decline in the assessment of chronic obstructive pulmonary disease progression. Am J Med 119(10 Suppl 1):4–11

    PubMed  Google Scholar 

  4. Diaz O, Villafranca C, Ghezzo H, Borzone G, Leiva A, Milic-Emil J, Lisboa C (2000) Role of inspiratory capacity on exercise tolerance in COPD patients with and without tidal expiratory flow limitation at rest. Eur Respir J 16:269–275

    CAS  PubMed  Google Scholar 

  5. Eltayara L, Becklake MR, Volta CA, Milic-Emili J (1996) Relationship between chronic dyspnea and expiratory flow-limitation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 154:1726–1734

    CAS  PubMed  Google Scholar 

  6. Hay JG, Stone P, Carter J, Church S, Eyre-Brook A, Pearson MG, Woodcock AA, Calverley PM (1992) Bronchodilator reversibility, exercise performance and breathlessness in stable chronic obstructive pulmonary disease. Eur Respir J 5:659–664

    CAS  PubMed  Google Scholar 

  7. O’Donnell DE (2006) Impatting patient-centred outcomes in COPD: breathlessness and exercise tolerance. Eur Respir Rev 15:37–41

    Google Scholar 

  8. Celli B, ZuWallack R, Wang S, Kesten S (2003) Improvement in resting inspiratory capacity and hyperinflation with tiotropium in COPD patients with increased static lung volumes. Chest 124:1743–1748

    PubMed  Google Scholar 

  9. Pellegrino R, Rodarte JR, Brusasco V (1998) Assessing the reversibility of airway obstruction. Chest 114:1607–1612

    CAS  PubMed  Google Scholar 

  10. Cooper CB (2006) The connection between chronic obstructive pulmonary disease symptoms and hyperinflation and its impact on exercise and function. Am J Med 119(10 Suppl 1):21–31

    PubMed  Google Scholar 

  11. O’Donnell DE, Laveneziana P (2006) The clinical importance of dynamic lung hyperinflation in COPD. COPD 3:219–932

    PubMed  Google Scholar 

  12. O’Donnell DE, Sciurba F, Celli B, Mahler DA, Webb KA, Kalberg CJ, Knobil K (2006) Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise endurance in COPD. Chest 130:647–656

    PubMed  Google Scholar 

  13. O’Donnell DE, Fluge T, Gerken F, Hamilton A, Webb K, Aguilaniu B, Make B, Magnussen H (2004) Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 23:832–840

    PubMed  Google Scholar 

  14. Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, Centanni S (2003) Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 21:86–94

    PubMed  Google Scholar 

  15. Newton MF, O’Donnell DE, Forkert L (2002) Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest 121:1042–1050

    CAS  PubMed  Google Scholar 

  16. Casanova C, Cote C, de Torres JP, Aguirre-Jaime A, Marin JM, Pinto-Plata V, Celli BR (2005) Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171:591–597

    PubMed  Google Scholar 

  17. Mahler DA (2006) Mechanisms and measurement of dyspnea in chronic obstructive pulmonary disease. Proc Am Thorac Soc 3:234–238

    PubMed  Google Scholar 

  18. Ries A (2006) Impact of chronic obstructive pulmonary disease on quality of life: the role of dyspnea. Am J Med 119(10 Suppl 1):12–20

    PubMed  Google Scholar 

  19. American Thoracic Society (1999) Dyspnea: mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med 159:321–340

    Google Scholar 

  20. Fletcher CM, Elmes PC, Fairbairn AS, Wood CH (1959) The significance of respiratory symptoms and the diagnosis of chronic bronchitis in a working population. Br Med J 5147:257–266

    Google Scholar 

  21. Mahler DA, Weinberg DH, Wells CK, Feinstein AR (1984) The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 85:751–758

    CAS  PubMed  Google Scholar 

  22. Williams JE, Singh SJ, Sewell L, Guyatt GH, Morgan MD (2001) Development of a self-reported Chronic Respiratory Questionnaire (CRQ-SR). Thorax 56:954–959

    CAS  PubMed  Google Scholar 

  23. Hickey AM, Bury G, O’Boyle CA, Bradley F, O’Kelly FD, Shannon W (1996) A new short form individual quality of life measure (SEIQoL-DW): application in a cohort of individuals with HIV/AIDS. Br Med J 313:29–33

    CAS  Google Scholar 

  24. Jones PW (2001) Health status measurement in chronic obstructive pulmonary disease. Thorax 56:880–887

    CAS  PubMed  Google Scholar 

  25. Jones PW, Quirk FH, Baveystock CM (1994) Why quality of life measures should be used in the treatment of patients with respiratory illness. Monaldi Arch Chest Dis 49:79–82

    CAS  PubMed  Google Scholar 

  26. Jones PW (2006) Health status: what does it mean for payers and patients? Proc Am Thorac Soc 3:222–226

    PubMed  Google Scholar 

  27. Jones PW, Bosh TK (1997) Changes in quality of life in COPD patients treated with salmeterol. Am J Respir Crit Care Med 155:1283–1289

    CAS  PubMed  Google Scholar 

  28. Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J, Felez M, Khalaf A, Marrades RM, Monso E, Serra-Batlles J, Anto JM (2002) Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166:680–685

    PubMed  Google Scholar 

  29. Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG (1997) Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax 52:67–71

    CAS  PubMed  Google Scholar 

  30. O’Boyle CA, McGee H, Hickey A, O’Malley K, Joyce CR (1992) Individual quality of life in patients undergoing hip replacement. Lancet 339:1088–1091

    PubMed  Google Scholar 

  31. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE (2006) Markers of disease severity in chronic obstructive pulmonary disease. Pulm Pharmacol Ther 19:189–199

    CAS  PubMed  Google Scholar 

  32. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T (2003) Analysis of the factors related to mortality in chronic obstructive pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 167:544–549

    PubMed  Google Scholar 

  33. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR (2004) The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 23:28–33

    CAS  PubMed  Google Scholar 

  34. Rabinovich RA, Vilaró J, Roca J (2004) Evaluation exercise tolerance in COPD patients: the 6-minute walking test. Arch Bronconeumol 40:80–85

    CAS  PubMed  Google Scholar 

  35. Killian KJ, Leblanc P, Martin DH, Summers E, Jones NL, Campbell EJ (1992) Exercise capacity and ventilatory, circulatory, and symptom limitation in patients with chronic airflow limitation. Am Rev Respir Dis 146:935–940

    CAS  PubMed  Google Scholar 

  36. Montes de Oca M, Rassulo J, Celli B (1996) Respiratory muscle and cardiopulmonary function during exercise in very severe COPD. Am J Respir Crit Care Med 154:1284–1289

    CAS  PubMed  Google Scholar 

  37. Montes de Oca M, Celli BR (2000) Respiratory muscle recruitment and exercise performance in eucapnic and hypercapnic severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161:880–885

    CAS  PubMed  Google Scholar 

  38. ATS/ACCP statement on cardiopulmonary exercise testing (2003) Am J Respir Crit Care Med 167:211–277

    Google Scholar 

  39. Belman MJ, Botnick WC, Shin JW (1990) Inhaled bronchodilators reduce dynamic hyperinflation during exercise in patients with COPD. Am J Respir Crit Care Med 153:967–975

    Google Scholar 

  40. O’Donnell DE, Webb KA (1993) Exertional breathlessness in patients with chronic airflow limitation: the role of hyperinflation. Am Rev Respir Dis 148:1351–1357

    PubMed  Google Scholar 

  41. O’Donnell DE, Lam M, Webb KA (1998) Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158:1557–1565

    PubMed  Google Scholar 

  42. O’Donnell DE, Revill SM, Webb KA (2001) Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:770–777

    PubMed  Google Scholar 

  43. Johnson BD, Weisman IM, Zeballos RJ, Beck KC (1999) Emerging concepts in the evaluation of ventilatory limitation during exercise: the exercise tidal flow-volume loop. Chest 116:488–503

    CAS  PubMed  Google Scholar 

  44. Gerardi DA, Lovett L, Benoit-Connors ML, Reardon JZ, ZuWallack RL (1996) Variables related to increased mortality following outpatient pulmonary rehabilitation. Eur Respir J 9:431–435

    CAS  PubMed  Google Scholar 

  45. Szekely LA, Oelberg DA, Wright C, Johnson DC, Wain J, Trotman-Dickenson B, Shepard JA, Kanarek DJ, Systrom D, Ginns LC (1997) Preoperative predictors of operative morbidity and mortality in COPD patients undergoing bilateral lung volume reduction surgery. Chest 111:550–558

    CAS  PubMed  Google Scholar 

  46. Cahalin L, Pappagianopoulos P, Prevost S, Wain J, Ginns L (1995) The relationship of the 6-min walk test to maximal oxygen consumption in transplant candidates with end-stage lung disease. Chest 108:452–459

    CAS  PubMed  Google Scholar 

  47. Guyatt GH, Townsend M, Keller J, Singer J, Nogradi S (1991) Measuring functional status in chronic lung disease: conclusions from a randomized control trial. Respir Med 85(Suppl B):17–21

    PubMed  Google Scholar 

  48. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt H (1997) Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med 155:1278–1282

    CAS  PubMed  Google Scholar 

  49. American Thoracic Society Statement (2002) Guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111–117

    Google Scholar 

  50. Papi A, Luppi F, Franco F, Fabbri LM (2006) Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 3:245–251

    PubMed  Google Scholar 

  51. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA (2000) Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 161:1608–1613

    CAS  PubMed  Google Scholar 

  52. Donaldson GC, Seemungal TA, Bhowmik A, Wedzicha JA (2002) Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57:847–852

    CAS  PubMed  Google Scholar 

  53. O’Reilly JF, Williams AE, Holt K, Rice L (2006) Defining COPD exacerbations: impact on estimation of incidence and burden in primary care. Prim Care Respir J 15:346–353

    PubMed  Google Scholar 

  54. Burge S, Wedzicha JA (2003) COPD exacerbations: definitions and classifications. Eur Respir J Suppl 41:46s–53s

    CAS  PubMed  Google Scholar 

  55. Pauwels R, Calverley P, Buist AS, Rennard S, Fukuchi Y, Stahl E, Löfdahl CG (2004) COPD exacerbations: the importance of a standard definition. Respir Med 98:99–107

    CAS  PubMed  Google Scholar 

  56. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320:1297–1303

    CAS  Google Scholar 

  57. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H (2003) Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22:912–919

    CAS  PubMed  Google Scholar 

  58. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA (1987) Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 106:196–204

    CAS  PubMed  Google Scholar 

  59. Sin DD, Wu L, Man SF (2005) The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 127:1952–1959

    PubMed  Google Scholar 

  60. Mannino DM, Reichert MM, Davis KJ (2006) Lung function decline and outcomes in an adult population. Am J Respir Crit Care Med 173:985–990

    PubMed  Google Scholar 

  61. Nocturnal Oxygen Therapy Trial Group (1980) Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease: a clinical trial. Ann Intern Med 93:391–398

    Google Scholar 

  62. Nishimura K, Izumi T, Tsukino M, Oga T (2002) Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121:1434–1440

    PubMed  Google Scholar 

  63. Landbo C, Prescott E, Lange P, Vestbo J, Almdal TP (1999) Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:1856–1861

    CAS  PubMed  Google Scholar 

  64. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R (2005) Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60:925–931

    CAS  PubMed  Google Scholar 

  65. Antonelli Incalzi R, Fuso L, De Rosa M, Forastiere F, Rapiti E, Nardecchia B, Pistelli R (1997) Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 10:2794–2800

    CAS  PubMed  Google Scholar 

  66. Man SF, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Sin DD (2006) C-reactive protein and mortality in mild to moderate chronic obstructive pulmonary disease. Thorax 61:849–853

    CAS  PubMed  Google Scholar 

  67. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ (2004) The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350:1005–1012

    CAS  PubMed  Google Scholar 

  68. Burrows B, Bloom JW, Traver GA, Cline MG (1987) The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 317:1309–1314

    CAS  PubMed  Google Scholar 

  69. Burrows B, Earle RH (1969) Prediction of survival in patients with chronic airways obstruction. Am Rev Respir Dis 99:865–871

    CAS  PubMed  Google Scholar 

  70. Boushy SF, Thompson HK Jr, North LB, Beale AR, Snow TR (1973) Prognosis in chronic obstructive pulmonary disease. Am Rev Respir Dis 108:1373–1383

    CAS  PubMed  Google Scholar 

  71. Martinez FJ, Foster G, Curtis JL, Criner G, Weinmann G, Fishman A, DeCamp MM, Benditt J, Sciurba F, Make B, Mohsenifar Z, Diaz P, Hoffman E, Wise R (2006) Predictors of mortality in patients with emphysema and severe airflow obstruction. Am J Respir Crit Care Med 173:1326–1334

    PubMed  Google Scholar 

  72. Sukumalchantra Y, Dinakara P, Williams MH Jr (1966) Prognosis of patients with chronic obstructive pulmonary disease after hospitalization for acute ventilatory failure: a three-year follow-up study. Am Rev Respir Dis 93:215–222

    CAS  PubMed  Google Scholar 

  73. Connors AF Jr, Dawson NV, Thomas C, Harrell FE Jr, Desbiens N, Fulkerson WJ, Kussin P, Bellamy P, Goldman L, Knaus WA (1996) Outcomes following acute exacerbation of severe chronic obstructive lung disease: the SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med 154:959–967

    PubMed  Google Scholar 

  74. Sin DD, Anthonisen NR, Soriano JB, Agusti AG (2006) Mortality in COPD: Role of comorbidities. Eur Respir J 28:1245–1257

    CAS  PubMed  Google Scholar 

  75. McGarvey LP, John M, Anderson JA, Zvarich M, Wise RA (2007) Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 62:411–415

    PubMed  Google Scholar 

  76. Cleverley JR, Muller NL (2000) Advances in radiologic assessment of chronic obstructive pulmonary disease. Clin Chest Med 21:653–663

    CAS  PubMed  Google Scholar 

  77. Zompatori M, Fasano L, Fabbri M, Maraldi F, Carvelli P, Laporta T, Pacilli A (1997) Assessment of the severity of pulmonary emphysema by computed tomography. Monaldi Arch Chest Dis 52:147–154

    CAS  PubMed  Google Scholar 

  78. Kalender WA, Rienmuller R, Seissler W, Behr J, Welke M, Fichte H (1990) Measurement of pulmonary parenchymal attenuation: use of spirometric gating with quantitative CT. Radiology 175:265–268

    CAS  PubMed  Google Scholar 

  79. Gevenois PA, De Vuyst P, Sy M, Scillia P, Chaminade L, de Maertelaer V, Zanen J, Yernault JC (1996) Pulmonary emphysema: quantitative CT during expiration. Radiology 199:825–829

    CAS  PubMed  Google Scholar 

  80. Bankier AA, De Maertelaer V, Keyzer C, Gevenois PA (1999) Pulmonary emphysema: subjective visual grading versus objective quantification with macroscopic morphometry and thin-section CT densitometry. Radiology 211:851–858

    CAS  PubMed  Google Scholar 

  81. Camiciottoli G, Bartolucci M, Maluccio NM, Moroni C, Mascalchi M, Giuntini C, Pistolesi M (2006) Spirometrically gated high-resolution CT findings in COPD: lung attenuation vs lung function and dyspnea severity. Chest 129:558–564

    PubMed  Google Scholar 

  82. Zaporozhan J, Ley S, Eberhardt R, Weinheimer O, Iliyushenko S, Herth F, Kauczor HU (2005) Paired inspiratory/expiratory volumetric thin-slice CT scan for emphysema analysis: comparison of different quantitative evaluations and pulmonary function test. Chest 128:3212–3220

    PubMed  Google Scholar 

  83. Cerveri I, Dore R, Corsico A, Zoia MC, Pellegrino R, Brusasco V, Pozzi E (2004) Assessment of emphysema in COPD: a functional and radiologic study. Chest 125:1714–1718

    PubMed  Google Scholar 

  84. Brown RH, Croisille P, Mudge B, Diemer F, Permutt S, Togias A (2000) Airway narrowing in healthy humans inhaling methacholine without deep inspirations demonstrated by HRCT. Am J Respir Crit Care Med 161:1256–1263

    CAS  PubMed  Google Scholar 

  85. Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, Reznek RH, Wedzicha JA (2004) Bronchiectasis, exacerbation indices, and inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170:400–407

    PubMed  Google Scholar 

  86. Hoffman EA, Reinhardt JM, Sonka M, Simon BA, Guo J, Saba O, Chon D, Samrah S, Shikata H, Tschirren J, Palagyi K, Beck KC, McLennan G (2003) Characterization of the interstitial lung diseases via density-based and texture-based analysis of computed tomography images of lung structure and function. Acad Radiol 10:1104–1118

    PubMed  Google Scholar 

  87. Chabat F, Yang GZ, Hansell DM (2003) Obstructive lung diseases: texture classification for differentiation at CT. Radiology 228:871–877

    PubMed  Google Scholar 

  88. Salerno M, de Lange EE, Altes TA, Truwit JD, Brookeman JR, Mugler JP 3rd (2002) Emphysema: hyperpolarized helium 3 diffusion MR imaging of the lungs compared with spirometric indexes - initial experience. Radiology 222:252–260

    PubMed  Google Scholar 

  89. Fain SB, Altes TA, Panth SR, Evans MD, Waters B, Mugler JP 3rd, Korosec FR, Grist TM, Silverman M, Salerno M, Owers-Bradley J (2005) Detection of age-dependent changes in healthy adult lungs with diffusion-weighted 3He MRI. Acad Radiol 12:1385–1393

    PubMed  Google Scholar 

  90. Yablonskiy DA, Sukstanskii AL, Leawoods JC, Gierada DS, Bretthors GL, Lefrak SS, Cooper JD, Conradi MS (2002) Quantitative in vivo assessment of lung microstructure at the alveolar level with hyperpolarized 3He diffusion MRI. Proc Natl Acad Sci USA 99:3111–3116

    CAS  PubMed  Google Scholar 

  91. Jones PW, Agusti AG (2006) Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 27:822–832

    CAS  PubMed  Google Scholar 

  92. Barnes PJ, Chowdhury B, Kharitonov SA, Magnussen H, Page CP, Postma D, Saetta M (2006) Pulmonary biomarkers in COPD. Am J Respir Crit Care Med 174:6–14

    CAS  PubMed  Google Scholar 

  93. Tzortzaki EG, Tsoumakidou M, Makris D, Siafakas NM (2006) Laboratory markers for COPD in “susceptible” smokers. Clin Chim Acta 364:124–138

    CAS  PubMed  Google Scholar 

  94. Gan WQ, Man SF, Senthilselvan A, Sin DD (2004) Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59:574–580

    CAS  PubMed  Google Scholar 

  95. Hurst JR, Perera WR, Wilkinson TMA, Donaldson GC, Wedzicha JA (2006) Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173:71–78

    CAS  PubMed  Google Scholar 

  96. Spruit MA, Gosselink R, Troosters T, Kasran A, Gayan-Ramirez G, Bogaerts P, Bouillon R, Decramer M (2003) Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 58:752–756

    CAS  PubMed  Google Scholar 

  97. Calikoglu M, Sahin G, Unlu A, Ozturk C, Tamer L, Ercan B, Kanik A, Atik U (2004) Leptin and TNF-α levels in patients with chronic obstructive pulmonary disease and their relationship to nutritional parameters. Respiration 71:45–50

    CAS  PubMed  Google Scholar 

  98. Roland M, Bhowmik A, Sapsford RJ, Seemungal TA, Jeffries DJ, Warner TD, Wedzicha JA (2001) Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease. Thorax 56:30–35

    CAS  PubMed  Google Scholar 

  99. Fiorini G, Crespi S, Rinaldi M, Oberti E, Vigorelli R, Palmieri G (2000) Serum ECP and MPO are increased during exacerbations of chronic bronchitis with airway obstruction. Biomed Pharmacother 54:274–278

    CAS  PubMed  Google Scholar 

  100. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW (2000) Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 84:210–215

    CAS  PubMed  Google Scholar 

  101. Stockley RA, Burnett D (1979) α-Antitrypsin and leukocyte elastase in infected and noninfected sputum. Am Rev Respir Dis 120:1081–1086

    CAS  PubMed  Google Scholar 

  102. Shindo K, Hirai Y, Fukumura M, Koide K (1997) Plasma levels of leukotriene E4 during clinical course of chronic obstructive pulmonary disease. Prostaglandins Leukot Essent Fatty Acids 56:213–217

    CAS  PubMed  Google Scholar 

  103. Franciosi LG, Page CP, Celli BR, Cazzola M, Walker MJ, Danhof M, Rabe KF, Della Pasqua OE (2006) Markers of exacerbation severity in chronic obstructive pulmonary disease. Respir Res 7:74

    PubMed  Google Scholar 

  104. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA (2006) Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174:867–874

    CAS  PubMed  Google Scholar 

  105. Stolz D, Christ-Crain M, Bingisser R, Leuppi J, Miedinger D, Muller C, Huber P, Muller B, Tamm M (2007) Antibiotic treatment of exacerbations of COPD: a randomized, controlled trial comparing procalcitonin-guidance with standard therapy. Chest 131:9–19

    CAS  PubMed  Google Scholar 

  106. Skeletal muscle dysfunction in chronic obstructive pulmonary disease (1999) A statement of the American Thoracic Society and European Respiratory Society. Am J Respir Crit Care Med 159:S1–S40

    Google Scholar 

  107. Schols AM (2000) Nutrition in chronic obstructive pulmonary disease. Curr Opin Pulm Med 6:110–115

    CAS  PubMed  Google Scholar 

  108. Schols AM, Wouters EF, Soeters PB, Westerterp KR (1991) Body composition by bioelectrical-impedance analysis compared with deuterium dilution and skinfold anthropometry in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 53:421–424

    CAS  PubMed  Google Scholar 

  109. Arora NS, Rochester DF (1982 Jul) Respiratory muscle strength and maximal voluntary ventilation in undernourished patients. Am Rev Respir Dis 126(1):5–8

    CAS  PubMed  Google Scholar 

  110. Wilson DO, Rogers RM, Wright EC, Anthonisen NR (1989) Body weight in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 139:1435–1414

    CAS  Google Scholar 

  111. Gray-Donald K, Gibbons L, Shapiro SH, Macklem PT, Martin JG (1996) Nutritional status and mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153:961–966

    CAS  PubMed  Google Scholar 

  112. Chailleux E, Fauroux B, Binet F, Dautzenberg B, Polu JM (1996) Predictors of survival in patients receiving domiciliary oxygen therapy or mechanical ventilation: a 10-year analysis of ANTADIR Observatory. Chest 109:741–749

    CAS  PubMed  Google Scholar 

  113. Schols AM, Slangen J, Volovics L, Wouters EF (1998) Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157:1791–1797

    CAS  PubMed  Google Scholar 

  114. Harik-Khan RI, Fleg JL, Wise RA (2002) Body mass index and the risk of COPD. Chest 121:370–376

    PubMed  Google Scholar 

  115. Vestbo J, Prescott E, Almdal T, Dahl M, Nordestgaard BG, Andersen T, Sorensen TI, Lange P (2006) Body Mass, Fat Free Body Mass and prognosis in COPD patients from a random population sample. Am J Respir Crit Care Med 173:79–83

    PubMed  Google Scholar 

  116. Engelen MP, Schols AM, Baken WC, Wesseling GJ, Wouters EF (1994) Nutritional depletion in relation to respiratory and peripheral skeletal muscle function in out-patients with COPD. Eur Respir J 7:1793–1797

    CAS  PubMed  Google Scholar 

  117. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF (1993) Prevalence and characteristics of nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 147:1151–1156

    CAS  PubMed  Google Scholar 

  118. Baarends EM, Schols AM, Mostert R, Wouters EF (1997) Peak exercise response in relation to tissue depletion in patients with chronic obstructive pulmonary disease. Eur Respir J 10:2807–2813

    CAS  PubMed  Google Scholar 

  119. Palange P, Forte S, Felli A, Galassetti P, Serra P, Carlone S (1995) Nutritional state and exercise tolerance in patients with COPD. Chest 107:1206–1212

    CAS  PubMed  Google Scholar 

  120. Engelen MP, Schols AM, Does JD, Wouters EF (2000) Skeletal muscle weakness is associated with wasting of extremity fat-free mass but not with airflow obstruction in patients with chronic obstructive pulmonary disease. Am J Clin Nutr 71:733–738

    CAS  PubMed  Google Scholar 

  121. Palange P, Forte S, Onorati P, Paravati V, Manfredi F, Serra P, Carlone S (1998) Effect of reduced body weight on muscle aerobic capacity in patients with COPD. Chest 114:12–18

    CAS  PubMed  Google Scholar 

  122. Mostert R, Goris A, Weling-Scheepers C, Wouters EF, Schols AM (2000) Tissue depletion and health related quality of life in patients with chronic obstructive pulmonary disease. Respir Med 94:859–867

    CAS  PubMed  Google Scholar 

  123. Pitta F, Troosters T, Spruit MA et al (2005) Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171:972–7

    PubMed  Google Scholar 

  124. Marquis K, Debigaré R, LeBlanc P et al (2002) Mid-thigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with COPD. Am J Respir Crit Care Med 166:809–813

    PubMed  Google Scholar 

  125. Schols AM, Broekhuizen R, Weling-Scheepers CA et al (2005) Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 82:53–59

    CAS  PubMed  Google Scholar 

  126. Bernard S, LeBlanc P, Whittom F, Carrier G, Jobin J, Belleau R, Maltais F (1998) Peripheral muscle weakness in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158:629–634

    CAS  PubMed  Google Scholar 

  127. Gosker HR, Lencer NH, Franssen FM, van der Vusse GJ, Wouters EF, Schols AM (2003) Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest 123:1416–1424

    PubMed  Google Scholar 

  128. Gosselink R, Troosters T, Decramer M (1996) Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 153:976–980

    CAS  PubMed  Google Scholar 

  129. Decramer M, Gosselink R, Troosters T, Verschueren M, Evers G (1997) Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 10:417–423

    CAS  PubMed  Google Scholar 

  130. Decramer M, de Bock V, Dom R (1996) Functional and histologic picture of steroid-induced myopathy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 153:1958–1964

    CAS  PubMed  Google Scholar 

  131. Gosker HR, Engelen MP, van Mameren H, van Dijk PJ, van der Vusse GJ, Wouters EF, Schols AM (2002) Muscle fiber type IIX atrophy is involved in the loss of fat-free mass in chronic obstructive pulmonary disease. Am J Clin Nutr 76:113–119

    CAS  PubMed  Google Scholar 

  132. Maltais F, Simard AA, Simard C, Jobin J, Desgagnes P, LeBlanc P (1996) Oxidative capacity of the skeletal muscle and lactic acid kinetics during exercise in normal subjects and in patients with COPD. Am J Respir Crit Care Med 153:288–293

    CAS  PubMed  Google Scholar 

  133. Wouters EF (2006) Muscle wasting in chronic obstructive pulmonary disease: to bother and to measure! Am J Respir Crit Care Med 173:4–5

    PubMed  Google Scholar 

  134. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PMA, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rutten-Van Molken M, Stockley R, Sullivan SA, Wedzicha JA, Wouters EF (2008) Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 31:416–468

    CAS  PubMed  Google Scholar 

  135. ZuWallack RL, Haggerty MC, Jones P (2004) Clinically meaningful outcomes in patients with chronic obstructive pulmonary disease. Am J Med 117(Suppl 12A):49S–59S

    PubMed  Google Scholar 

  136. Celli BR, Calverley PM, Rennard SI, Wouters EF, Agusti A, Anthonisen N et al (2005) Proposal for a multidimensional staging system for chronic obstructive pulmonary disease. Respir Med 99:1546–1554

    PubMed  Google Scholar 

  137. Cote CG, Celli BR (2005) Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 26:630–636

    CAS  PubMed  Google Scholar 

  138. Imfeld S, Bloch KE, Weder W, Russi EW (2006) The BODE index after lung volume reduction surgery correlates with survival. Chest 129:873–878

    PubMed  Google Scholar 

  139. Make B (2003) COPD: developing comprehensive management. Respir Care 48:1225–1237

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Respiratory Diseases, Department of Internal Medicine, University of Rome, Rome, Italy

    Mario Cazzola

  2. Division of Pulmonary Sciences and Critical, National Jewish Medical and Research Center, University of Colorado School of Medicine, Denver, CO, USA

    Barry J. Make

Authors
  1. Mario Cazzola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Barry J. Make
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario Cazzola .

Editor information

Editors and Affiliations

  1. , Section of Pulmonary and Critical Care M, Baylor College of Medicine, 1504 Taub Loop, Houston, 77030, Texas, USA

    Nicola A. Hanania

  2. Michael E. DeBakey VA Medical Center, Baylor College of Medicine, 2002 Holcombe Blvd., Houston, 77030, Texas, USA

    Amir Sharafkhaneh

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Cazzola, M., Make, B.J. (2011). Outcome Measures and Prognostic Markers for COPD. In: Hanania, N., Sharafkhaneh, A. (eds) COPD. Respiratory Medicine. Humana Press. https://doi.org/10.1007/978-1-59745-357-8_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59745-357-8_4

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-58829-949-9

  • Online ISBN: 978-1-59745-357-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation